Active Recruiting Trials: Seize Your Spot in Cutting-Edge Research Now!
Spots are filling fast—don’t miss your chance for free expert care, innovative treatments, and compensation that could transform your health. All qualifying participants receive study medications, supplies, labs, and exams at no cost. Browse trials below by condition, check eligibility in seconds, and submit our quick pre-screening form to get matched today. Your breakthrough awaits!
We’ve organized these trials by condition for easy scanning. Each one is Active – Recruiting right now. Click through to learn more and take action.
Type 1 Diabetes Trials
Pioneering weekly insulin options to simplify management and stabilize blood sugar.
| Trial Name | Sponsor | Study Focus | Duration | Age | Action Steps |
|---|---|---|---|---|---|
| Onward 11 / NN1436-8181 | Novo Nordisk | Comparing once-weekly Insulin Icodec vs. once-daily Insulin Glargine U100 in adults with Type 1 Diabetes | 26 Weeks | ≥18 |
Type 2 Diabetes & Obesity Trials
Target weight loss, glucose control, and metabolic health with next-gen therapies.
| Trial Name | Sponsor | Study Focus | Duration | Age | Action Steps |
|---|---|---|---|---|---|
| Zupreme 2 / ZP8396-24115 | Zealand Pharma | Efficacy and safety of Petrelintide for overweight/obesity and Type 2 Diabetes | 28 Weeks | ≥18 |
|
| GZPO | Eli Lilly | Orforglipron (LY3502970) for obesity/overweight and Type 2 Diabetes | 78 Weeks | ≥18 |
|
| ReCET / 898 | Endogenex | Endoscopic Intestinal Re-Cellularization Therapy for Type 2 Diabetes | 52 Weeks | 18–70 |
|
| Solstice / D761C00001 | AstraZeneca | Once-daily AZD5004 vs. placebo for Type 2 Diabetes | 26 Weeks | ≥18 |
Obesity Trials
Innovative solutions for sustainable weight management and better metabolic outcomes.
(Note: Some obesity trials overlap with Type 2 Diabetes—see above for dual-focus options like Zupreme 2 and GZPO.)
Cardiovascular Trials
Protecting Your Heart by Redefining Your Weight.
| Trial Name | Sponsor | Study Focus | Duration | Age | Action Steps |
|---|---|---|---|---|---|
| MARITIME-CV / 20220196 |
Amgen Inc. | Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity |
Up to approximately 35 months | ≥45 |
|
Chronic Kidney Disease Trials
Advanced combos to slow progression, manage proteinuria, and reduce cardiovascular risks.
| Trial Name | Sponsor | Study Focus | Duration | Age | Action Steps |
|---|---|---|---|---|---|
| BaxDuo Pacific / D6972C00002 | AstraZeneca | Baxdrostat + Dapagliflozin for CKD with proteinuria and high blood pressure | 24 Months | 18+ |
|
Hypothyroidism Trials
Natural thyroid alternatives to boost energy and thyroid balance.
| Trial Name | Sponsor | Study Focus | Duration | Age | Action Steps |
|---|---|---|---|---|---|
| Avanti / M21-341 | AbbVie | Armour Thyroid vs. synthetic T4 for primary hypothyroidism | 81 Weeks | 18–75 |
|
Why Wait? Every Trial Offers:
✔ Zero-Cost Care: Meds, labs, exams—all covered.
✔ Expert Monitoring: Frequent check-ins with top specialists.
✔ Potential Compensation: For time and travel (details per trial).
✔ Real Impact: Advance medicine while prioritizing your health.
Thousands have already taken the step—what’s holding you back?
Your health upgrade starts here. Enroll today and step into tomorrow’s medicine!
Ready to Qualify? Act Fast—Enrollment is Limited!
Call now! 407-480-4836